Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus Ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase i trial

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Hayton, Emma Jo ^a   Rose, Annie ^a   Ibrahimsa, Umar ^a   Sorbo, Mariarosaria Del ^b   Capone, Stefania ^b   Crook, Alison ^a   Black, Antony P ^a,d   Dorrell, Lucy ^a,c   Hanke, Tomáš ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Okairos ^*  (Italy)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Institut Pasteur du Laos   (Laos)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEMOGLOBIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; PLASMID DNA; POTASSIUM; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; RECOMBINANT VACCINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LOW DRUG DOSE; MALAISE; MALE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIMIAN VIRUS; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SKIN DEFECT; SKIN DISCOLORATION; SKIN INDURATION; SKIN ULCER; SWELLING; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION; VACCINIA VIRUS; VACCINIA VIRUS ANKARA; VOMITING; ADOLESCENT; BLOOD; CLINICAL TRIAL; GENE VECTOR; GENETICS; HEK293 CELL LINE; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PLASMID; VIRUS REPLICATION; YOUNG ADULT;

ADENOVIRUSES, SIMIAN; ADOLESCENT; ADULT; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CONSERVED SEQUENCE; FEMALE; GENETIC VECTORS; HEK293 CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MALE; MIDDLE AGED; PLASMIDS; SINGLE-BLIND METHOD; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRUS REPLICATION; YOUNG ADULT;

EID: 84903954106     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101591     Document Type: Article

References (43)

1. Letourneau S, Im E-J, Mashishi T, Brereton C, Bridgeman A, et al. (2007) Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2: e984.
2. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, et al. (2003) Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 17: 2581-2591. (Pubitemid 38402336)
3. Ferguson AL, Mann JK, Omarjee S, Ndung'u T, Walker BD, et al. (2013) Translating HIV Sequences into Quantitative Fitness Landscapes Predicts Viral Vulnerabilities for Rational Immunogen Design. Immunity 38: 606-617.
4. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, et al. (2001) Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 193: 375-386.
5. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 282-289. (Pubitemid 38667619)
6. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, et al. (2012) Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4: 1-9.
7. Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, et al. (2010) Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 40: 1973-1984.
8. Knudsen ML, Mbewe-Mvula A, Rosario M, Johansson DX, Kakoulidou M, et al. (2012) Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to conventional plasmid DNA vaccine. J Virol 86: 4082-4090.
9. Rosario M, Borthwick N, Stewart-Jones GB, Mbewe-Mwula A, Bridgeman A, et al. (2012) Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. AIDS 26: 275-284.
10. Ondondo B, Brennan C, Nicosia A, Crome S, Hanke T (2013) Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice Vaccine 31: 5594-5601.
11. Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, et al. (2014) Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 22: 464-475.
12. Bejon P, Peshu N, Gilbert SC, Lowe BS, Molyneux CS, et al. (2006) Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 42: 1102-1110.
13. Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, et al. (2006) Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24: 417-425. (Pubitemid 41832544)
14. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, et al. (2010) Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 5: e13983.
15. Dorrell L, Williams P, Suttill A, Brown D, Roberts J, et al. (2007) Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25: 3277-3283. (Pubitemid 46527996)
16. Graham B, Koup R, Roederer M, Bailer R, Enama M, et al. (2006) Phase I Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate DNA Vaccine. J Infect Dis 194: 1650-1660. (Pubitemid 44901995)
17. Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, et al. (2008) Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26: 2788-2795.
18. McCormack S, Stohr W, Barber T, Bart PA, Harari A, et al. (2008) EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 26: 3162-3174.
19. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, et al. (2012) Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205: 772-781.
20. Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, et al. (2012) Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 7: e31208.
21. Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, et al. (2013) ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 20: 2355-2368.
22. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, et al. (2012) Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19: 2269-2276.
23. Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, et al. (2013) Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS ONE 8: e57726.
24. Aste-Amezaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, et al. (2004) Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 15: 293-304. (Pubitemid 38365918)
25. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
26. Paris R, Kuschner RA, Binn L, Thomas SJ, Colloca S, et al. (2014) Adenovirus type 4 and type 7 vaccination or type 4 respiratory infection elicit minimal cross-reactive antibody to non-human adenovirus vaccine vectors. Clin Vaccine Immunol.
27. Hanke T (2014) Conserved immunogens in prime-bost strategies for te next-generation HIV-1 vaccines. Expert Opin Biol Ther 14: 601-616.
28. Estcourt MJ, McMichael AJ, Hanke T (2004) DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 199: 144-155. (Pubitemid 38736769)
29. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, et al. (2006) Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24: 4554-4561. (Pubitemid 43776762)
30. Im E-J, Hanke T (2004) MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 3: S89-97. (Pubitemid 39120629)
31. Mehendale S, Thakar M, Sahay S, Kumar M, Shete A, et al. (2013) Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers. PLoS One 8: e55831.
32. Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, et al. (2009) A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 25: 1107-1116.
33. Sutter G, Staib C (2003) Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3: 263-271. (Pubitemid 37139046)
34. Gilbert P, Follmann D (2013) Presentation of meta-analysis. Mini-Summit on Adenovirus Platforms for HIV Vaccines. Bethesda, Maryland, U.S.A. http://www.totalwebcasting.com/view/?id=niaid.
35. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, et al. (2013) Reply to Richie and Villasante. J Infect Dis 207: 690-692.
36. Duerr A, Wasserheit JN, Corey L (2006) HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 43: 500-511. (Pubitemid 44157161)
37. Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, et al. (2014) Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis.
38. Richie TL, Villasante EF (2013) Use of adenovirus serotype 5 vaccine vectors in seropositive, uncircumcised men: safety lessons from the step trial. J Infect Dis 207: 689-690.
39. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, et al. (2013) Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. N Engl J Med.
40. Dudareva M, Andrews L, Gilbert SC, Bejon P, Marsh K, et al. (2009) Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27: 3501-3504.
41. Hutnick NA, Carnathan D, Demers K, Makedonas G, Ertl HC, et al. (2010) Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine 28: 1932-1941.
42. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, et al. (2012) Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122: 359-367.
43. Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, et al. (2012) A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 7: e41936.